Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.51 |
| ▸ | MMP2 | P08253 | 5/20 | 0.49 |
| ▸ | MMP3 | P08254 | 5/20 | 0.49 |
| ▸ | MMP9 | P14780 | 5/20 | 0.49 |
| ▸ | MMP13 | P45452 | 5/20 | 0.49 |
| ▸ | MMP1 | P03956 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841892 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL1841540 | 0.94 | GPR139 (0.57) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL4216415 | 0.94 | GPR139 (0.57) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL379512 | 0.94 | GPR139 (0.57) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL5514590 | 0.93 | GPR139 (0.51) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL1844872 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL1841923 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL4221498 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL4210499 | 0.91 | MMP2 (0.49) | SMN1; SMN2GPR139MMP2MMP3MMP9 | |
| SCHEMBL1841931 | 0.91 | MMP2 (0.49) | SMN1; SMN2GPR139MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710261-B2 | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | RANBAXY LABORATORIES LIMITED (IN) | 2014-04-29 | — | — | US | claimed |
| EP-1856063-B1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LAB LTD (IN) | 2012-01-25 | — | — | EP | claimed |
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-08-14 | — | — | US | claimed |
| US-8710261-B2 | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | RANBAXY LABORATORIES LIMITED (IN) | 2014-04-29 | — | — | US | disclosed |
| EP-1856063-B1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LAB LTD (IN) | 2012-01-25 | — | — | EP | disclosed |
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-08-14 | — | — | US | disclosed |
| EP-1856063-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | Ranbaxy Laboratories Limited (IN) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090235-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | F2RL3, ACOX3, LPAR5 | SMN1; SMN2 3836/4885GPR139 873/4885MMP2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.